Abstract
T is a novel anti-PD-L1 antibody and A is a multi-kinase inhibitor. This study aims to evaluate the efficacy and safety of T in combination with A in the treatment of advanced STS. Preliminary results had disclosed the potential of this regimen, here we report the results based on the expanded sample size and updated data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
